Dyania Health, a healthcare technology company using artificial intelligence to streamline patient chart reviews, has closed a $10 million Series A funding round. The round was led by HealthX Ventures, with significant backing from Tech Square Ventures and Cleveland Clinic Ventures, alongside existing investors. This funding underscores a growing interest in Dyania’s solutions aimed at tackling inefficiencies in data management and clinical research across the healthcare industry.
Founded in 2020, Dyania Health was established by CEO Eirini Schlosser with a mission to develop proprietary AI technology that could support clinicians by automating one of healthcare’s most labor-intensive tasks: manual chart review. Schlosser, driven by a vision to bridge healthcare and technology, brought together a unique team of physicians and AI researchers, creating a model that combines clinical insight with advanced AI capabilities. Together, they worked to create Synapsis, Dyania’s proprietary platform, which is built to handle complex chart review tasks with remarkable speed and accuracy.
The Synapsis AI platform is now being implemented in major healthcare systems, where it automates pre-screening for clinical trials, assists in chart reviews for observational studies, and simplifies registry reporting. This platform is positioned to significantly reduce manual workload for healthcare providers, allowing them to deliver more precise and timely patient care.
During development, Schlosser’s team made strategic investments in GPU resources to optimize the AI’s computing power. By annotating large datasets with input from full-time clinicians, the team trained Synapsis to a level that now consistently outperforms human experts in chart review accuracy, a critical achievement in the field.
The investment led by HealthX Ventures reflects a shared belief in Dyania’s potential to transform clinical processes through advanced technology, allowing for streamlined healthcare operations and faster medical research.
